Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Retatrutide vs Tiragratide
An educational, source-based comparison of Retatrutide and Tiragratide — how each peptide works, what it's researched for, and what to know before going deeper.
A synthetic peptide that simultaneously agonizes GLP-1, GIP, and glucagon receptors. The glucagon component is hypothesized to add energy expenditure on top of the appetite suppression and insulinotropic effects of GLP-1/GIP.
- Obesity and weight loss (Phase 3)
- Type 2 diabetes
- NAFLD/MASH
- • Investigational; not FDA-approved (Phase 3 ongoing).
- • GI side effects common, similar to other incretin therapies.
- • Requires physician oversight.
Investigational triple hormone receptor agonist for metabolic disease.
An investigational peptide agonist targeting GLP-1, GIP, and glucagon receptors. Similar mechanism to retatrutide, designed to maximize weight loss while preserving lean mass through multi-pathway metabolic modulation.
- Obesity and metabolic syndrome
- Type 2 diabetes glycemic control
- NAFLD and liver fat reduction
- • Investigational; not yet FDA-approved.
- • Requires physician oversight in clinical trials.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Retatrutide | Triple-hormone-receptor agonist retatrutide for obesity | New England Journal of Medicine | 2023 | Phase 2 trial showed up to ~24% body weight reduction at 48 weeks. |
| Tiragratide | Tiragratide Phase 2 trial in obesity | Diabetes Care | 2025 | Demonstrated significant weight reduction with favorable GI tolerability profile. |
Side-effect & safety grid
- Investigational; not FDA-approved (Phase 3 ongoing).
- GI side effects common, similar to other incretin therapies.
- Requires physician oversight.
- Investigational; not yet FDA-approved.
- Requires physician oversight in clinical trials.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Retatrutide vs Tiragratide — Key differences
- Class: Retatrutide is classified as Metabolic · Incretin, while Tiragratide is Metabolic · Incretin.
- Primary research focus: Retatrutide — obesity and weight loss (phase 3); Tiragratide — obesity and metabolic syndrome.
- Tag: Weight loss vs Metabolic.